BioLife Solutions (NASDAQ:BLFS – Get Free Report) is projected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $29.13 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.
BioLife Solutions (NASDAQ:BLFS – Get Free Report) last posted its earnings results on Thursday, August 6th. The medical equipment provider reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.88. The company had revenue of $28.47 million for the quarter, compared to analyst estimates of $27.80 million. BioLife Solutions had a return on equity of 2.70% and a net margin of 53.29%. On average, analysts expect BioLife Solutions to post $0.03 EPS for the current fiscal year and $0.16 EPS for the next fiscal year.
BioLife Solutions Stock Performance
Shares of BioLife Solutions stock opened at $38.61 on Thursday. The company has a market capitalization of $1.89 billion, a PE ratio of 33.28 and a beta of 1.82. The company has a 50-day simple moving average of $37.46 and a two-hundred day simple moving average of $27.81. BioLife Solutions has a one year low of $17.86 and a one year high of $39.76.
Analyst Ratings Changes
Read Our Latest Stock Report on BLFS
About BioLife Solutions
BioLife Solutions, Inc develops and supplies products and services used to preserve, process, store and transport biological materials. Its solutions support the development and manufacture of cell and gene therapies, including products designed to help maintain the viability and functionality of cells, tissues and other biologic materials throughout the bioprocessing workflow.
The company’s portfolio includes preservation media such as CryoStor and HypoThermosol, cell thawing and handling products, and related storage and shipping systems.
Further Reading
- Five stocks we like better than BioLife Solutions
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
